NEW YORK – Myongji Hospital in South Korea's Gyeonggi Province said Monday that it has signed an agreement with Next&Bio to jointly establish a bank of patient-derived organoids that researchers will use to advance precision cancer treatments.
In this collaboration, Seoul, South Korea-based Next&Bio will contribute its organoid culture and production technology and will begin building the organoid bank with the hospital in October. Initially, the partners will focus on developing organoids from patients with liver, stomach, colon, and pancreatic cancers, though they will add organoids of other tumor types in the future.
Researchers at Myongji Hospital will lend their clinical research expertise and use these organoids to screen patients for personalized therapies and to discover new biomarkers. The hospital is hoping to expand its ability to develop precision cancer therapies with these organoids, which enable the study of drugs in human tumor models and may reduce the need for animal models. Myongji Hospital's anti-cancer immune cell therapy technology and Next&Bio's immune cell therapy screening platform will also be used for precision drug development efforts in this collaboration.
Meanwhile, "Next&Bio is discussing various business operations with major domestic and foreign research institutes in the field of developing new drugs using organoids, for evaluating the validity and toxicity of new drug candidates," Next&Bio CEO Lee Young-wook said in a statement.